Cellworks Wins Dell Technologies The Challengers 2022 Innovative Business of the Year Award
Leading Genomic Biosimulation Company Recognized for its High Performance Computing (HPC) Cloud Infrastructure
SOUTH SAN FRANCISCO, Calif., September 7, 2022 – Cellworks Group, Inc., a world leader in Genomic Biosimulation Services for Precision Pharma and Personalized Oncology, today announced it has won The Challengers Innovative Business of the Year Award. Dell Technologies, in collaboration with Moneycontrol, CNBC TV-18, Intel, and Ernst and Young, established The Challengers Awards to recognize the agility and innovation displayed by IT innovators.
The Challengers 2022 Innovative Business of the Year Award recognizes Cellworks’ exemplary IT innovation through the establishment of a high performance computing (HPC) cloud infrastructure in a colocation center in Bangalore. The Cellworks cloud infrastructure consistently optimizes effective usage of infrastructure services with respect to compute, security, storage, auto health monitors, and alerts to power the Cellworks Biosimulation Platform, which runs the company’s groundbreaking Computational Omics Biology Model (CBM).
“We are honored to receive this recognition from Dell Technologies and other industry leaders,” said Yatin Mundkur, Chief Technology Officer and Board Director at Cellworks Group. “This award underscores our commitment to continue to scale the analytics infrastructure necessary to power our Biosimulation Platform, which delivers Precision Pharma and Personalized Oncology services to biotech, pharma and healthcare organizations worldwide.”
The 2022 Challengers Awards included the following categories: healthcare & life science, technology - IT/ITES & telecommunication; energy OEM/industrial products; travel, logistics and supply chain; and other businesses. More than 100 businesses qualified for an extensive evaluation that was led by independent partners Moneycontrol and Ernst and Young. Award winners were declared at a grand awards ceremony in New Delhi on August 25, 2022.
Cellworks Biosimulation Platform
The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment. The platform is powered by Cellworks groundbreaking Computational Omics Biology Model (CBM), a network of 7,000+ human genes, 30,000+ molecular species and 100+ signaling pathways. As part of the biosimulation process, personalized disease models are created for each patient using their cytogenetic and molecular data as input to the Cellworks CBM. The Cellworks platform analyzes the impact of specific therapies on the patient’s personalized disease model and generates a SingulaTM biosimulation report with Therapy Response Index (TRI) scores from 0 to 100 that predict low to high therapeutic benefit.
About Cellworks Group
Cellworks Group, Inc. is a world leader in Genomic Biosimulation Services for Precision Pharma and Personalized Oncology. Using innovative multi-omics modeling, computational biosimulation and Artificial Intelligence heuristics, Cellworks predicts the most efficacious therapies for patients. The Cellworks unique biosimulation platform is a unified representation of biological knowledge curated from heterogeneous datasets and applied to finding cures. Backed by UnitedHealth Group, Sequoia Capital, Agilent and Artiman, Cellworks has the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers and software technologists working toward a common goal – attacking serious diseases to improve the lives of patients. The company is based in South San Francisco, California and has a research and development facility in Bangalore, India. For more information, visit www.cellworks.life and follow us on Twitter @cellworkslife.
All trademarks and registered trademarks in this document are the properties of their respective owners.
Reichert Communications, LLC